Rafael Holdings prioritizes Trappsol Cyclo development, CEO stepping down. TransportNPC Phase 3 trial fully enrolled, results in mid-2025.

Unusual Whales
2025.04.24 20:37
The Phase 3 clinical trial of TransportNPC™ by Cyclo Therapeutics for treating Niemann-Pick Disease Type C1, a rare genetic condition, has completed enrollment. The trial is evaluating Trappsol® Cyclo™ and interim analysis results are anticipated in mid-2025 after 48 weeks of study. This marks a significant advancement in the research for this fatal disease.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.